secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0000950170-23-050236
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix reports FY2023 results: FDA authorization, 55% test growth, $11M cost cuts
--------------------------------------------------------------------------------

- FDA De Novo marketing authorization for KidneyIntelX.dkd to assess kidney decline risk in diabetic patients.
- Over 5,000 KidneyIntelX tests performed in FY2023, up 55% from prior year.
- Reduced annual operating expenses by over $11M vs prior year; additional cuts underway.
- Completed $20.3M equity financing in February 2023 led by new institutional investors.
- Secured multiple insurance contracts including EmblemHealth and CareFirst; over 40 commercial payors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/0000950170-23-050236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/rnlx-20230928.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-050236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer